Economic Observation Network The core dynamic of New Bridge Biotech (NBP. US) in the past week is pipeline expansion layout.

Business Progress
On October 13th, Visara, the ophthalmic subsidiary of the company, exclusively introduced VIS-102 (nerve growth factor therapy) from Wuhan Haite Biotechnology, obtaining global ophthalmic rights except for Greater China The Ib phase data showed that the highest dose group had a 50% complete corneal healing rate after 8 weeks, with good efficacy signals, but the sample size was small and still early data. While promoting pipeline diversification, the company is also sharing the risk of a single asset.

The above content is based on publicly available information and does not constitute investment advice.